Oral targeted drugs for rectal cancer are as follows: 1. Regorafenib: Regorafenib is the first oral small molecule targeted drug for the treatment of colon cancer, which can comprehensively act on tumor cell proliferation, tumor angiogenesis and tumor microenvironment-related targets, thus exerting multiple anti-tumor effects. Regorafenib is currently approved for the treatment of patients with metastatic colorectal cancer who have previously received fluorouracil-based, oxaliplatin, irinotecan-based chemotherapy, as well as those who have previously received or are not suitable for anti-vascular endothelial growth factor therapy or anti-epidermal growth factor receptor therapy. The dosage of regorafenib is generally 160 mg/day with a 3-week discontinuation. Regorafenib can improve patients’ survival and reduce the risk of death, with higher safety, better tolerability and patient compliance; 2. Furoquintinib: Furoquintinib is a new type of highly selective targeting vascular endothelial growth factor receptor, also a small molecule inhibitor, which can effectively inhibit vascular endothelial growth factor receptor, so as to achieve the purpose of inhibiting angiogenesis and killing tumor cells. The dosage of furoquinitinib is 5 mg orally once daily for 28 days is 1 cycle, which can significantly prolong the survival and progression-free survival of patients. Furoquinitinib has been approved for marketing and is one of the standard third-line therapeutic agents for metastatic colorectal cancer.